Renata Karaś

Mrs. Renata Karaś

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
RKRenata Karaś
Renata Karaś
UBUrszula Ewa Binduga
Urszula Ewa Binduga
PJPaweł Januszewicz
Paweł Januszewicz
Konrad Andrzej SzychowskiKonrad Andrzej Szychowski
Konrad Andrzej Szychowski
Obesity is a chronic systemic disease characterised by insulin resistance, inflammation, and mitochondrial dysfunction. Hyperbaric oxygen therapy (HBOT), which involves the administration of 100% oxygen under elevated atmospheric pressure, has a well-established clinical application in the treatment of non-healing wounds and ischemia, and it is currently being investigated as an adjunctive therapy for obesity and metabolic disorders. The aim of this review is to provide a critical synthesis of recent (2012–2025) evidence regarding the mechanisms of HBOT action in the human body. Furthermore, it examines the metabolic effects and safety profile of HBOT in the context of obesity, with particular attention to experimental and preliminary clinical research. Preclinical studies have demonstrated that HBOT enhances insulin sensitivity, reduces adipose tissue inflammation, and modulates lipid metabolism. The proposed mechanisms include activation of Akt/AMPK signalling and GLUT4 translocation in skeletal muscle, resulting in improved glucose uptake and oxidation, as well as stimulation of thermogenesis in brown adipose tissue. In rodent models of obesity, HBOT has been shown to reduce adipose tissue mass, improve lipid profiles, and restore normal β-oxidation of fatty acids by normalising the expression of peroxisome proliferator-activated receptor-α and carnitine palmitoyl transferase 1B in muscle tissue. Preliminary clinical studies in humans indicate that HBOT enhances both systemic and tissue insulin sensitivity, accompanied by improved mitochondrial function and reduced endoplasmic reticulum stress. Despite these promising findings, data on the long-term efficacy, optimal treatment protocols, and safety of HBOT in obese individuals remain limited. In conclusion, HBOT appears to be a promising adjunctive approach in the management of obesity through the multidirectional improvement in metabolic functions. However, high-quality clinical trials are required to confirm its effectiveness, durability of outcomes, and safety profile across diverse patient populations.

Verified
Journal Article
Open access
PDF file
RKRenata Karaś
Renata Karaś
UBUrszula Ewa Binduga
Urszula Ewa Binduga
Konrad Andrzej SzychowskiKonrad Andrzej Szychowski
Konrad Andrzej Szychowski
Dietary nucleotides and nucleic-acid-derived compounds are considered bioactive nutrients, but their metabolic relevance remains uncertain. This narrative review, supported by a structured literature search, evaluates intestinal handling and evidence on glucose and lipid metabolism, redox homeostasis, immune function, gut barrier regulation, and microbiota. Direct supplementation studies are distinguished from nucleoside/nucleobase evidence, dietary nucleic acids or purine-rich foods, and endogenous extracellular purinergic signaling. Preclinical studies suggest defined nucleotide preparations may modulate AMP-activated protein kinase (AMPK), insulin receptor substrate 1 (IRS-1)/protein kinase B (AKT)/forkhead box protein O1 (FOXO1) signaling, lipid accumulation, and mitochondrial/redox-related endpoints. In contrast, extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine 5′-monophosphate (AMP) studies provide mechanistic context but do not show that oral supplementation modifies purinergic signaling in humans. Human intervention evidence is sparse and derived from older adults not selected for insulin resistance, type 2 diabetes, or metabolic-dysfunction-associated steatotic liver disease (MASLD). Reductions in homeostatic model assessment of insulin resistance (HOMA-IR) should be interpreted as changes in a surrogate estimate, not proof of therapeutic efficacy. The supplemental doses evaluated in available human intervention studies appear generally well-tolerated, whereas short-term high nucleotide intake can raise circulating uric acid. Dietary nucleotides therefore remain candidate, not established, metabolic or immune therapies.